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SN-38 is the active metabolite of irinotecan and it is metabolised through conjugation by uridine diphosphate glucuronosyl transferase
(UGT1A1). The major toxicity of irinotecan therapy is diarrhoea, which has been related to the enzymatic activity of UGT1A1. We
examined the influence of the UGT1A1 gene promoter polymorphism in the toxicity profile, in the response rate and in the overall
survival (OS) in 95 patients with metastatic colorectal cancer treated with an irinotecan-containing chemotherapy. Genotypes were
determined by analysing the sequence of TATA box of UGT1A1 of genomic DNA from the patients. Clinical parameters and
genotypes were compared by univariate and multivariate statistical methods. The more frequent adverse effects were asthenia (34
patients), diarrhoea (29 patients) and neutropenia (20 patients). Severe diarrhoea was observed in 7/10 homozygous (70%) and 15/
45 heterozygous (33%) in comparison to 7/40 (17%) wild-type patients (P¼0.005). These results maintained the statistical
significance in logistic regression analysis (P¼0.01) after adjustment for other clinical relevant variables. The presence of severe
haematological toxicity increased from wild-type patients to UGT1A1*28 homozygotes, but without achieving statistical significance.
No relationship was found between the UGT1A1*28 genotypes and infection, nausea or mucositis. In univariate studies, patients with
the UGT1A1*28 polymorphism showed a trend to a poorer OS (P¼0.09). In the multivariate analysis, the genotype was not related
to clinical response or to OS. The role of the UGT1A1 genotype as a predictor of toxicity in cancer patients receiving irinotecan
demands the performance of a randomized trial to ascertain whether genotype-adjusted dosages of the drug can help to establish
safe and effective doses not only for patients with the UGT1A1*28 homozygous genotype but also for those with the most common
UGT1A1 6/6 or 6/7 genotype.
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Irinotecan (CPT-11) is currently used in cancer chemotherapy
given its ability to inhibit topoisomerase I (Jaxel et al, 1989; Bissery
et al, 1996; Zamboni et al, 1998). On the basis of large randomised
clinical trials, irinotecan either alone or in combination with
fluorouracil has been accepted as first- or second-line chemother-
apy for the treatment of patients with colorectal cancer (Cunning-
ham et al, 1998; Rougier et al, 1998; Douillard et al, 2000; Saltz et al,
2000). The most common side effects are bone marrow toxicity,
leading to abnormally low blood counts, and ileocolitis, which
often results in severe diarrhoea (Vanhoefer et al, 2001). These
adverse effects impair the therapeutic efficacy, and could result in
the discontinuation of an otherwise effective anticancer treatment.
Irinotecan is mainly eliminated unchanged by the liver and to a
minor extent by the kidneys (Mathijssen et al, 2001). The drug
follows two metabolic pathways that take place in the liver. It can
be converted into an inactive metabolite by the CYP3A4
cytochrome (Haaz et al, 1998) and into an active metabolite, SN-
38, by carboxylesterase enzymes (Slatter et al, 1997). SN-38 is
further metabolised through conjugation into SN-38 glucuronide
(SN-38G) by uridine diphosphate glucuronosyltransferase
(UGT1A1), the same enzyme that conjugates bilirubin (Iyer et al,
1998).
In a study performed to investigate the effect of glucuronidation
on the concentration of SN-38 following irinotecan infusion in 21
patients undergoing a phase I trial, an inverse relationship between
SN-38 glucuronidation rates and severity of diarrhoea has been
reported, indicating that glucuronidation of SN-38 might protect
against irinotecan-induced gastrointestinal toxicity (Gupta et al,
1994). An interesting case-report on two patients with metastatic
colorectal cancer and Gilbert’s syndrome (a chronic nonhaemo-
lytic unconjugated hyperbilirrubinaemia caused by a reduction in
the activity of UGT1A1) treated with CPT-11 provided the first
clinical evidence linking deficiency in the UGT1A1 activity and
irinotecan-related toxicity (Wasserman et al, 1997).
The UGT1A locus in humans is located in the long arm of
chromosome 2 (2q37) and spans approximately 160kb. The
UGT1A1 gene consists of at least nine promoters and first exons
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l(first exons 3, 11 and 12 are pseudogenes) that can be spliced with
four common exons to result in nine different UGT1A1
enzymes (Ritter et al, 1992; Owens and Ritter, 1995). More
than 50 genetic variations in the promoter and coding regions
of the gene are currently known to decrease the enzyme
activity (Kadakol et al, 2000), leading to constitutional
unconjugated jaundice (Crigler-Najjar or Gilbert’s syndromes).
One of the most common genotypes causing Gilbert’s syndrome
in Caucasian populations is the inheritance of a promoter
region containing an extra TA dinucleotide [A(TA)7TAA], which
results in a 70% reduction in transcriptional activity com-
pared with wild-type UGT1A1 [A(TA)6TAA]. Patients who are
either heterozygous or homozygous for this variant allele
(designated as UGT1A1*28) exhibit an attenuated expression of
UGT1A1 and are theoretically predisposed to SN-38 initiated
diarrhoea (Ando et al, 2000). Furthermore, in a human liver
microsome experimental model, a significant trend towards a
decrease in SN-38 and bilirrubin glucuronidation rates was
found as the number of TA dinucleotide repeats increased
(6/646/747/7) (Iyer et al, 1999).
In the present study, we examined the influence of uridine
diphosphate glucuronosyl transferase UGT1A1 polymorphism on
the toxicity profile, on the response rate and on the overall survival
(OS) in patients with metastatic colorectal cancer treated with an
irinotecan-containing chemotherapy.
MATERIALS AND METHODS
Patients
In all, 95 patients diagnosed with metastatic colorectal cancer and
undergoing irinotecan-based chemotherapy were studied. All
patients were primarily ensured to have an adequate bone marrow
and organ function before the use of irinotecan. The exclusion
criteria were ECOG X3 and apparent jaundice. All patients gave
written informed consent, and the study was approved by the
Institutional Ethics Committee.
Chemotherapy regimen description
We used four different regimens in this group of patients.
Regimen A consisted of irinotecan alone (350mgm
2 infused in
45min i.v. every 3 weeks). Regimen B consisted of irinotecan at
the same dose and intervals with Tomudex (3mgm
2 infused in
15min i.v. in every cycle). Regimen C consisted of irinotecan
(80mgm
2 infused in 45min i.v. every week) with a dose of
2250mgm
2 of 5-FU (in continuous infusion during 48h i.v.) in
every cycle. Regimen D consisted of irinotecan (180mgm
2 every 2
weeks i.v.) and 5-FU with leucovorin i.v. Patients underwent
chemotherapy cycles until severe toxicity or disease progression
(DP) appeared.
Clinical parameters
Relevant clinical data were obtained from clinical records (gender,
age, ECOG, previous surgery or radiotherapy, line of chemother-
apy, actual dosage of irinotecan, and use of G-CSF). Two serum
total bilirubin levels were analysed: just prior to irinotecan
administration and the highest value after initiation of therapy.
Toxicity was graded in accordance with the WHO scale: presence
and grade of nausea, asthenia, mucositis, diarrhoea, infection,
neutropenia, anaemia and thrombocytopenia. Response to treat-
ment and OS were also analysed. Complete remission (CR) was
defined as the disappearance of tumor masses and disease-related
symptoms, as well as the normalisation of the initially abnormal
tests and/or biopsies lasting for at least 1 month. Partial remission
(PR) was considered when measurable lesions decreased by at least
50%. Clinical response was assumed when a complete or PR was
obtained. Patients without criteria of clinical response but without
progression were considered patients with stable disease (SD).
Disease progression during or after treatment was also considered.
Overall survival was calculated from the start of chemotherapy to
death regardless of the cause.
UGT1A1 genotyping assay: Genomic DNA was extracted from
peripheral leukocytes by the salting-out procedure (Miller et al,
1989). Analysis of the A(TA)nTAA motif in the promoter region of
the UGT1A1 gene was performed by PCR, according to Monaghan
et al (1996), followed by separation of the amplified products on a
12% polyacrylamide gel (38:2 acrylamide:bisacrylamide). Follow-
ing this protocol, DNA fragments containing six TA repeats
measure 98bp while those containing seven TA repeats occur as
100bp bands. Automated sequencing was performed to confirm
these sizes (Figure 1).
Statistical analysis
Differences between categorical variables were measured by the
w
2 test. Differences between means in continuous variables
were measured by: the Mann–Whitney U test when the variables
were two and unrelated, the Wilcoxon signed-rank test when
the variables were two and related, and analysis of variance
when we had more than two unrelated variables. Logistic
regression was used as a multivariate method to ascertain
whether the UGT1A1 genotype independently predicted toxicities
significantly related to this variable in previous univariate
analysis. Kaplan–Meier estimates and the log-rank test were the
methods used in univariate analysis of OS. A Cox-regression model
was used for OS multivariate analysis. The results were considered
as statistically significant when bilateral P-values were less
than 0.05.
RESULTS
Clinical and chemotherapy data and adverse effects
A total of 95 patients who fulfilled all inclusion and exclusion
criteria were studied. Clinical data, chemotherapy characteristics
and response to treatment are shown in Table 1. Severe toxicities
(Grades III–IV) were frequent in this group of patients. In total,
55% (58%) suffered from some kind of grade III/IV adverse effect
and 28 out of these patients (48%) developed more than two severe
adverse effects at the same time. The most frequent severe adverse
effects were asthenia (34 patients), diarrhoea (29 patients) and
neutropenia (20 patients).
98 pb
6/6 6/6 6/7 6/7 6/7 7/7 7/7
40 50 40 50
A
B
100 pb
Figure 1 Analysis of the A(TA)nTAA motif, in the promoter region of
the UGT1A1 gene. Pattern of polyacrylamide gel electrophoresis: DNA
bands of 98bp correspond to alleles containing six TA repeats. DNA bands
of 100pb correspond to alleles containing seven TA repeats. Automated
sequencing of the DNA fragments with six and seven TA repeats.
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The total serum bilirubin level prior to therapy and the highest
level during the chemotherapy cycles were measured and were
related to the UGT1A1 genotype. The results are shown in Table 2.
Differences in the mean of bilirubin levels of the three genotypes
were significant pre- and postchemotherapy. Bilirubin levels
increased significantly when chemotherapy was initiated in 6/6
patients (P¼0.01) and in 6/7 patients (P¼0.001); in the group of
7/7 patients, this increase, although very marked, did not attain
significance (P¼0.1) because of the small number of cases.
UGT1A1 genotype and toxicity
The allelic frequency of UGT1A1*28 in the group of patients
analysed was 0.34 (IC95%, 0.28–0.41), within the range reported in
Caucasian populations. Table 3 shows the univariate relationships
between the UGT1A1 genotypes and severe adverse effects (grades
III and IV). There was a marked relationship between the
appearance of severe diarrhoea (P¼0.005) and asthenia
(P¼0.03) and the heterozygous and homozygous UGT1A1*28
condition. These two variables were clearly related: 53% of patients
with severe diarrhoea also had severe asthenia, whereas 82% of the
patients who did not develop severe asthenia did not have
diarrhoea either (P¼0.001). In these cases, it may be assumed that
the variable related to the genotype was diarrhoea causing
asthenia. The presence of severe haematological toxicity (grades
III/IV neutropenia, anaemia or thrombocitopenia) increased from
wild-type patients to UGT1A1*28 homozygotes, but did not
achieve statistical significance. No relationship was found between
the UGT1A1*28 genotypes and infection, nausea or mucositis.
We have compared the preteatment levels of serum bilirrubin
between the group of 29 patients with grades III–IV diarrhea (9.6–
5.5mmoll
 1) and the group of 65 patients without this adverse
effect (9.1–3.7mmoll
 1). No significant differences were observed.
(P¼0.5).
A logistic regression model was constructed to ascertain whether
UGT1A1*28 genotype was independently related to the appearance
of severe diarrhoea. Table 4 shows the results of this multivariate
model. The UGT1A1 genotype was the only variable that
significantly predicted the appearance of severe diarrhoea. Other
variables included in the model but with no statistical significance
were age, gender, performance status, pretreatment levels of serum
bilirrubin, previous surgery or radiotherapy, chemotherapy regi-
men and lines of chemotherapy.
UGT1A1*28 genotypes, efficacy of treatment and OS
Although in univariate studies, patients with the UGT1A1*28
polymorphism did not have a statistically different probability of
achieving a clinical response (P¼0.3), they showed a trend to a
poorer OS (median OS 33 months for 6/6 patients vs 21 months for
6/7 and 7/7 patients, P¼0.09) (Figure 2). In the multivariate
analysis no genotype was related to clinical response or to OS
(P¼0.1 and 0.8, respectively).
DISCUSSION
Although more than 50 genetic lesions in the UGT1A1 gene have
been described (Kadakol et al, 2000), the UGT1A1*28 allele (the
most frequent polymorphism in Caucasian populations) plays a
crucial role in the development of toxicity after irinotecan
chemotherapy.
Table 1 Baseline characteristics of the 74 patients, chemotherapy and
response to treatment.
Gender (men/women) 60 (63%)/35 (37%)
Median age (range, year) 68 (25–83)
Performance status
0 46 (48%)
1 29 (31%)
2 0 (21%)
Previous treatment
Surgery 93 (98%)
Radiotherapy 11 (12%)
Chemotherapy treatment
CPT-11 alone 12 (13%)
CPT-11 and Tomudex 9 (9%)
CPT-11 and 5FU 18 (19%)
CPT-11 and 5FU+LV 56 (59%)
Line of chemotherapy
First line 57 (60%)
XSecond line 38 (40%)
Mean total actual dosage mgm
 2 (range) 1660 (180–6300)
Use of G-CSF
Yes 10 (11%)
Not 85 (89%)
Objective response
Complete or partial 26 (27%)
Stable disease 32 (34%)
Progressive disease 22 (23%)
Not evaluable 15 (16%)
Table 2 UGT1A1*28 genotypes and bilirubin levels (mmoll
 1) prior to
irinotecan administration and the highest value during therapy
Genotype
a N
Bilirubin premean
(range)
Bilirubin higher
mean (range) P*
6/6 40 8.3 (4–22) 9.9 (4–25) 0.001
6/7 45 8.7 (4–18) 13 (5–37) 0.001
7/7 10 15 (6–28) 22 (6–65) 0.1
P — 0.001 0.001
aSymbols of (6/6), (6/7) and (7/7) denote homozygous absence of the variant allele,
heterozygous, and homozygous for the variant allele, respectively. P¼Significance of
comparisons of bilirubin levels between genotypes. P*¼Significance of comparisons
of bilirubin levels pre- and postchemotherapy.
Table 3 Associations between UGT1A1*28 genotypes and grade III–IV toxicities
Genotype
a N Asthenia Diarrhoea Haematological Nausea Mucositis Infection
6/6 40 10 (25%) 7 (17%) 6 (15%) 5(12%) 1 (3%) 6 (15%)
6/7 45 17 (38%) 15 (33%) 12 (27%) 10 (22%) 2 (4%) 2 (4%)
7/7 10 7 (70%) 7 (70%) 4 (40%) 2 (20%) 0 (0%) 0 (0%)
P — 0.03 0.005 0.2 0.4 0.4 0.13
aSymbols of (6/6), (6/7), and (7/7) denote homozygous absence of the variant allele, heterozygous and homozygous for the variant allele, respectively. Bold values refer to
statistically significant values.
UGT1A1 gene variations and irinotecan treatment
E Marcuello et al
680
British Journal of Cancer (2004) 91(4), 678–682 & 2004 Cancer Research UK
C
l
i
n
i
c
a
lIn a preliminary study with nine patients, Ando et al (1998)
observed a lower glucuronidation rate of SN-38 in a patient with
genotype 7/7 vs those with genotypes 6/7 (n¼1) and 6/6 (n¼7),
suggesting that the patient with genotype 7/7 had an impaired
capacity for glucuronidation of SN-38.
In a subsequent work, these authors observed a heightened
sensitivity to irinotecan induced toxicity in a retrospective
and case-controlled study with 118 Japanese patients with
different cancers (Ando et al, 2000). They reported a frequency
of the UGT1A1*28 allele 3.5-fold higher in patients with
toxicity (severe diarrhoea or leukopenia) compared with
patients without this complication (Po0.0001). Multivariate
analysis indicated that the presence of the UGT1A1*28
allele turned out to be a risk factor for severe toxicity (Po0.001;
odds ratio, 7.23; 95% confidence interval, 2.52–22.3). A trend to
a better response of patients who experienced toxicity was
observed, but this had no statistical significance. The authors
suggested that the determination of the UGT1A1 genotypes might
be clinically useful for predicting severe toxicity by irinotecan
in cancer patients.
The pharmacogenetic assessment of UGT1A1 polymorphism
was also investigated in 20 patients with several primary
malignancies who were treated with irinotecan at a dose of
300mgm
2 every 3 weeks (Iyer et al, 2002). Circulating levels of SN-
38 were higher in those patients harbouring the TA7 allele. The
time course of the ratio of plasma concentration of SN-38G to SN-
38 indicated much lower glucuronidation rates of SN-38 for
patients with genotypes 6/7 and 7/7 when compared with those
that were homozygous 6/6 at each blood sampling time. There was
a significant progressive reduction in SN-38 glucuronidation rates
and a significant increase in AUC SN-38 values in patients with
genotype 6/7 and 7/7. All the patients with two wild-type alleles
had no/low diarrhoea or mild leukopenia. Severe grades of
diarrhoea and neutropenia were scored only in patients with
genotypes 6/7 and 7/7. However, the differences were not
statistically significant for neutropenia or diarrhoea grades among
the three genotypes.
In a recent work (Mathijssen et al, 2003), an exhaustive genotype
analysis of the irinotecan pathway was carried out in 65 cancer
patients treated with irinotecan (200–350mgm
2 in an i.v. 90-min
infusion). The extent of SN-38 glucuronidation was slightly
impaired in homozygous variants of UGT1A1*28, although
differences were not statistically significant given the very low
frequency of the variant allele in this group of patients. Only two
patients were UGT1A1*28 homozygotes and one of them was the
only patient in the entire cohort to suffer from grade IV diarrhoea.
In the present work, which includes 95 patients with metastatic
colorectal cancer, a statistically significant relationship, in both
univariate and multivariate analyses, was found between the
appearance of severe diarrhoea and the homozygote UGT1A1*28
genotype when compared with UGT1A1 wild-type patients. We
found no relationship between haematological toxicity and
genotype.
To our knowledge, this is the first pharmacogenetic
study carried out exclusively on patients with colorectal cancer.
In our series, 98% of patients had been submitted to surgery
and 12% to local radiotherapy. This could account for both
the high frequency of severe diarrhoea observed and the
statistically significant association of this adverse effect with
the UGT1A1 genotype.
Levels of bilirubin pre- and postchemotherapy were different for
each genotype (6/6, 6/7 and 7/7). Median bilirubin levels increased
significantly with treatment in 6/6 and 6/7 patients. Although the
increase was particularly marked in 7/7 patients (7mmoll
 1),
statistical significance was not achieved because of the small
number of patients (n: 10).
No improvement was observed in the clinical responses in
carriers and/or homozygous cases of UGT1A1*28, but a trend to a
better survival (P¼0.09) was found in ‘wild-type’ patients in
univariate analysis. These findings could be the result of a
reduction in the dosing of irinotecan in UGT1A1*28 carriers and/
or homozygous (because of the appearance of severe diarrhoea). In
fact, doses of CPT-11 administered in each genotypic group were
1725mgm
2 in 6/6, 1659mgm
2 in 6/7 and 1398mgm
2 in 7/7. These
doses have a decreasing tendency although the differences were
not significant (P¼0.2).
Anticancer agents are usually administered in accordance with
the body-surface area, but in the case of irinotecan, this parameter
does not have a clinically meaningful correlation with any
pharmacokinetic parameter. The UGT1A1 genotype would there-
fore be more useful than the body-surface area in the pharmaco-
kinetics of irinotecan (Mathijssen et al, 2002).
The available information regarding the role of the
UGT1A1 genotype as a predictor of toxicity in cancer patients
receiving irinotecan demands the performance of a randomized
trial to ascertain whether genotype-adjusted dosages of the
drug can help to establish safe and effective doses not only for
patients with the UGT1A1*28 homozygous genotype but also for
those with the most common UGT1A1 6/6 or 6/7 genotype.
Irinotecan studies have paved the way for new genetic-based ways
of applying chemotherapeutic treatments in a more rational
manner.
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Table 4 Multiple logistic regression analysis for variables independent
and significantly related to the presence of severe diarrhoea
Term b s.e. v
2 P Odds ratio (95% CI)
Intercept  1.5 0.5
UGT1A1 9.0 0.01
UGT1A1 +/  0.9 0.5 3 0.1 2.4 (0.9–6.6)
UGT1A1 +/+ 2.4 0.8 8.8 0.03 11 (2.3–5.3)
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Figure 2 Overall survival of patients with ‘wild-type’ UGT1A1
(continuous line) and patients heterozygous and homozygous for
UGT1A1*28 (dotted line); P¼0.07.
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